All News

Oral semaglutide delivers significant weight loss in OASIS trials, offering needle-free obesity therapy.

Updated ASTCT infectious disease guidelines reshape approaches to prophylaxis, treatment thresholds, and drug-drug interactions in opportunistic infections.

GoodRx's David Graziano breaks down how fluctuating acquisition costs, narrow formularies, and retrospective reimbursement adjustments are squeezing independent pharmacies—and what solutions exist to help them remain competitive.

Evaluating, implementing, and optimizing automation technologies that improve safety, efficiency, and patient care outcomes are practical strategies for health-system pharmacy leaders.

Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.

Pharmacy Times speaks with Caitlin Jones, PHD, on how evidence gaps, opioid dependence, and misaligned incentives can undermine pain care.

This FAQ outlines current measles cases, key drivers of increasing cases, and the essential role pharmacists play in vaccination, patient counseling, case recognition, and combating vaccine misinformation.

Lavinia Salama, PharmD, joins Craig Beavers, PharmD, to discuss implementing the 2026 CKM guidelines in clinical practice.

Supported by improved progression-free survival outcomes in the phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, sacituzumab govitecan-hziy received FDA approval as both a monotherapy and combination therapy with pembrolizumab.

The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).

Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.

The agent is to be used alongside diet adjustments in adult patients.

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about who should carry naloxone, common misconceptions surrounding overdose reversal and fentanyl-related overdoses, and the broader strategies needed to reduce overdose deaths.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.

A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.

Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.

Marijuana’s move to Schedule III has reignited a long-standing contradiction.

Pharmacists should be up-to-date on current outbreak status, US risk level, and how to recognize warning signs and counsel concerned patients as confirmed Ebola cases caused by Bundibugyo ebolavirus continue to rise across the Democratic Republic of the Congo (DRC) and Uganda.

Chiadi Ndumele, MD, breaks down the cardiovascular-kidney-metabolic syndrome (CKM) guideline's glucagon-like peptide-1 (GLP-1) and kidney-protective therapy guidance—and the pharmacist's role in coordinated care.

In this interview, Chris Elder, PharmD, BCOP, discusses major themes from OPC 2026, including advances in immunotherapy delivery, practical applications of ASCO and EHA data, and the expanding role of oncology pharmacists in optimizing patient care.

The new indication is for patients aged 12 and older with unresectable or metastatic SS who received prior chemotherapy and are positive for various genetic subtypes.

In this interview, Sonia Amin Thomas, PharmD, BCOP, AFMCP, INHC, discusses common challenges in precision medicine implementation and how oncology pharmacists can build expertise in biomarker interpretation, pharmacogenomics, and multidisciplinary care.

Findings from a retrospective analysis show that montelukast prophylaxis significantly reduced rituximab infusion-related reactions, particularly among patients receiving treatment for oncology indications.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.

Pharmacy Times speaks with Caitlin Jones, PHD, on opioids, spinal cord stimulators, and treatment-related harms in chronic low back pain.

Incorporate important health screenings and lifestyle prevention tips in MTM consults.